The FDA has approved three doses—1.5 mg, 4 mg, and 9 mg—of a new oral formulation of semaglutide for the treatment of type 2 diabetes as Ozempic tablets, Novo Nordisk announced.[1] Ozempic tablets contain the same active ingredient semaglutide as the injectable version and the previously approved oral drug Rybelsus.[1] The approval confirms the comparable efficacy and safety of the new tablet formulation based on bioequivalence studies and the broader clinical program of semaglutide.[1] Semaglutide belongs to the group of drugs GLP-1 receptor agonists, which mimic the natural hormone glucagon-like peptide 1.[1] The tablets will be available in the US in the second quarter of 2026.[1] Novo Nordisk has filed a refill application for a 25 mg Ozempic tablet for adults with type 2 diabetes, an FDA decision is expected by the end of 2026.[1] Patients should continue their current treatment until consultation with a physician.[1]